Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Kodiak Sciences scores big wins for wet AMD treatment. Both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) met their primary endpoints in the phase 3 DAYBREAK study, matching aflibercept on vision gains while showing promising safety profiles. Notably, more than half of Zenkuda patients achieved a 6-month dosing interval — a potential game-changer for patient convenience.
Kodiak Sciences' two wet AMD drugs clear a major hurdle
Kodiak Sciences announced that both Zenkuda (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) met the primary endpoint of noninferiority in best corrected visual acuity (BCVA) compared to aflibercept (Eylea) at one year in the phase 3 DAYBREAK study. Both agents are built on Kodiak's proprietary antibody biopolymer conjugate (ABC) platform, designed to sustain drug levels longer in the eye.
Zenkuda, an anti-VEGF therapy, not only matched aflibercept on vision gains but also delivered fast and sustained retinal drying — with over half of patients achieving a 6-month dosing interval. KSI-501, a bispecific anti-IL-6/VEGF-trap, hit both its primary vision endpoint and a secondary anatomical endpoint. Kodiak plans a post hoc analysis to identify which patients benefit most from IL-6 inhibition.
By the Numbers
50% of Zenkuda patients achieved a 6-month dosing interval
Why it matters: Kodiak plans to file a biologics license application for Zenkuda this year across three indications — wet AMD, diabetic retinopathy, and macular edema from retinal vein occlusion. If approved, Zenkuda's extended dosing schedule could significantly reduce treatment burden for patients managing chronic retinal diseases.
